Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evexomostat + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- SynDevRx
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous, Intravenous
01
Overview
Evexomostat + 5-fluorouracil is an investigational combination therapy developed by SynDevRx for the treatment of metabolic hormone-sensitive melanoma. Evexomostat (SDX-7320) is a first-in-class, polymer-conjugated small molecule inhibitor of methionine aminopeptidase 2 (MetAP2). By irreversibly binding to MetAP2, evexomostat modulates metabolic hormones such as insulin, leptin, and adiponectin, while also inhibiting angiogenic factors like bFGF and VEGF-C. 5-fluorouracil is a classic antimetabolite chemotherapy that inhibits thymidylate synthase. This combination aims to address both the tumor biology and the systemic metabolic dysfunction often associated with cancer progression. It is currently in Phase 1 clinical development.
- Other names
- SDX-7320 + 5-fluorouracilevexomostat + 5-FU
02
Targets
METAP2 (Methionine aminopeptidase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on evexomostat + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evexomostat + 5-fluorouracil.